Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11161473 | 0.79 | KEAP1 (0.57) | CYP2D6CYP2C19KEAP1NFE2L2HIF1A | |
| SCHEMBL16709856 | 0.78 | KEAP1 (0.61) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL16709845 | 0.78 | KEAP1 (0.61) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL20832990 | 0.78 | CYP2D6 (0.62) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL16709844 | 0.78 | KEAP1 (0.61) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL16709855 | 0.78 | KEAP1 (0.61) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL20850805 | 0.78 | KEAP1 (0.61) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL22259913 | 0.78 | CYP2D6 (0.62) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 | |
| SCHEMBL2762931 | 0.77 | CHRM2 (0.56) | CYP2D6CYP2C19KEAP1NFE2L2HIF1A | |
| Pipradrol SCHEMBL156360 | 0.77 | CYP2D6 (0.87) | CYP2D6CYP2C19KDM4ENPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153168-B1 | PHACETOPERANE FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER AND SYNTHESIS METHOD | NLS PHARMA AG (CH) | 2020-02-26 | — | — | EP | claimed |
| US-20220054471-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | NLS PHARMACEUTICS AG (CH) | 2022-02-24 | — | — | US | disclosed |
| US-20200061044-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2020-02-27 | — | — | US | disclosed |
| US-10456387-B2 | Phacetoperane for treating of attention deficit hyperactivity disorder | NLS PHARMACEUTICS AG (CH) | 2019-10-29 | — | — | US | disclosed |
| US-20180214436-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | NLS-1 PHARMA AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20150038533-A1 | PHACETOPERANE FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER | NLS PHARMA AG (CH) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038533-A1 | PHACETOPERANE FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER | COMT, DDT, QDPR | CYP2D6 122/4885CYP2C19 301/4885KDM4E 1410/4885 |
| US-20180214436-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | COMT, DDT, QDPR | CYP2D6 122/4885CYP2C19 254/4885KDM4E 1372/4885 |
| US-10456387-B2 | Phacetoperane for treating of attention deficit hyperactivity disorder | COMT, DDT, QDPR | CYP2D6 122/4885CYP2C19 254/4885KDM4E 1372/4885 |
| US-20200061044-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | COMT, DDT, QDPR | CYP2D6 122/4885CYP2C19 254/4885KDM4E 1372/4885 |
| US-20220054471-A1 | PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | COMT, DDT, QDPR | CYP2D6 122/4885CYP2C19 254/4885KDM4E 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.